Dose Insider / Glossary / Washout

WashoutWhat it means and when a GLP-1 label asks for one

Updated November 20, 2026 路 3 min read 路 FDA and DailyMed labels, MedlinePlus, 2025-2026

A washout, or washout period, is a planned stretch of time without a medicine before something else starts: another medicine, a trial or a test. It lets the first drug leave the body, or at least fall low enough not to interfere.

14 daysMAOI and Contrave or Qsymia, gaps the labels set
Gaps the labels setDays between stopping one and starting the nextMAOI and Contrave or Qsymia14 daysOpioids before naltrexone7 to 10 daysWegovy shot to Wegovy tablets7 daysWegovy tablets to Wegovy shot1 daysGaps the labels setDays between stopping one and starting the nextMAOI and Contrave or Qsymia14 daysOpioids before naltrexone7 to 10 daysWegovy shot to Wegovy tablets7 daysWegovy tablets to Wegovy shot1 days

Wegovy to Zepbound has no set gap; Zepbound starts at 2.5 mg.

On this page

For GLP-1 medicines the labels set short, specific gaps for a few moves between forms of semaglutide, and none at all for the move from Wegovy to Zepbound.1,2,3

Between forms of a GLP-1

The one-week gap from a weekly shot to a daily tablet matches the injection schedule: the tablet takes over on the day the next shot would have been due.

From Wegovy to Zepbound

No label sets a washout between semaglutide and tirzepatide. The Zepbound label starts everyone at 2.5 mg a week for 4 weeks and says it should not be combined with any GLP-1 receptor agonist. In practice the old drug is stopped and the new one starts at its own first step.3 Semaglutide is still fading during that time: the Ozempic label says it stays in the circulation for about 5 weeks after the last dose.4 Our page on switching from Wegovy to Zepbound shows how the two levels overlap.

Gaps with other medicines

The weight medicines that are not GLP-1s have stricter gaps, mostly for safety.

Before a planned pregnancy

The longest gap on a GLP-1 label concerns pregnancy. Because of semaglutide's long half-life, the Wegovy label advises stopping it at least 2 months before a planned pregnancy.1 That is a washout in all but name: time for the drug to clear before conception.

Before surgery or sedation

People often ask whether a GLP-1 medicine needs a washout before an operation. The labels do not set one. The Zepbound label notes rare reports of pulmonary aspiration under general anesthesia or deep sedation in people on GLP-1 medicines, some of whom had food left in the stomach despite fasting as instructed. It says the available data are not enough to recommend how to lower that risk, and asks patients to tell their care team about any planned surgery or procedure.3 Whether to pause the medicine is then decided by that team.

In clinical trials

Trials use washouts so that an earlier medicine does not blur the result. In the Trulicity label's 26-week trial of the drug on its own, people who had been on another diabetes medicine went through a two-week washout before randomization.8 When a study reports results after a washout, the starting values describe people off their previous treatment, which is worth knowing when comparing numbers across trials.

In practice

A washout is set by the label or the prescriber, never by guesswork. Stopping one medicine early to make room for another can leave a stretch with no treatment, and starting too soon can stack two drugs that should not be combined. The date of the last dose of the old medicine is the number everything else is counted from.

Sources

  1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2.5 and 8.3. accessdata.fda.gov
  2. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, version published August 19, 2026; sections 2.3 and 2.4. dailymed.nlm.nih.gov
  3. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2 and 5. accessdata.fda.gov
  4. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 12.3. accessdata.fda.gov
  5. QSYMIA (phentermine and topiramate extended-release capsules) prescribing information. Vivus LLC; DailyMed, version published April 24, 2026; section 4. dailymed.nlm.nih.gov
  6. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets prescribing information. DailyMed, version published November 17, 2025; sections 4 and 7. dailymed.nlm.nih.gov
  7. MedlinePlus. Naltrexone. U.S. National Library of Medicine; last revised September 15, 2026, read November 20, 2026. medlineplus.gov
  8. TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, version published August 10, 2026; section 14.2. dailymed.nlm.nih.gov

Related analyses

Log the last dose of one medicine and the first of the next, and see the gap on your calendar.

Open Dose Insider